Search Results for "Metabolic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Metabolic. Results 121 to 130 of 240 total matches.

Opill — An OTC Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
the metabolism of norgestrel and decrease its effectiveness. Recent studies suggest that concurrent use of non ...
The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC Opill is intended to increase access to effective contraception and reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2   doi:10.58347/tml.2023.1685c |  Show IntroductionHide Introduction

Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023  (Issue 1690)
single dose vials Metabolism Minimal Minimal Elimination Urine (75-85%) Urine (78%) Half-life 2.15 ...
The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90   doi:10.58347/tml.2023.1690c |  Show IntroductionHide Introduction

Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
Route Oral Formulation 100 mg tablets, 25 mg/mL suspension Tmax 3 hours Metabolism Primarily ...
Tovorafenib (Ojemda – Day One), a type II RAF kinase inhibitor, has received accelerated approval from the FDA for treatment of patients ≥6 months old with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or a BRAF V600 mutation. Tovorafenib is the first systemic treatment to be approved in the US for pediatric low-grade gliomas with BRAF fusions. Accelerated approval of tovorafenib was based on response rates and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8   doi:10.58347/tml.2024.1704f |  Show IntroductionHide Introduction

Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025  (Issue 1723)
. DRUG INTERACTIONS — DXd is metabolized primarily by CYP3A4; coadministration with strong CYP3A4 ...
The FDA has approved datopotamab deruxtecan (Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2   doi:10.58347/tml.2025.1723e |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
are not significantly metabolized by CYP isozymes and are less likely to interact with other drugs ▶ Simvastatin ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction

Molnupiravir - An Oral Antiviral Drug for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
with molnupiravir have been identified. It is not metabolized by CYP450 isozymes and is only minimally excreted ...
The investigational oral antiviral drug molnupiravir (Merck/Ridgeback Biotherapeutics) was granted an FDA Emergency Use Authorization (EUA) on December 23, 2021 for treatment of mild to moderate COVID-19 in outpatients ≥18 years old who are at high risk of progressing to severe disease, including hospitalization or death (see Table 1), and for whom alternative treatment options are not available or clinically appropriate. Paxlovid (Pfizer), nirmatrelvir copackaged with ritonavir, was granted an EUA on December 22, 2021. The IV antiviral drug remdesivir (Veklury) was approved by the...
Med Lett Drugs Ther. 2022 Jan 24;64(1642):10-1 |  Show IntroductionHide Introduction

Adagrasib (Krazati) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
family inhibitor Formulation 200-mg tablets Route Oral Tmax ~6 hours Metabolism Primarily by CYP3A4 ...
Adagrasib (Krazati – Mirati Therapeutics), a RAS GTPase family inhibitor, has received accelerated approval from the FDA for oral treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who received at least one prior systemic therapy. Accelerated approval was based on the objective response rate and duration of response.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):e17-8   doi:10.58347/tml.2023.1668f |  Show IntroductionHide Introduction

Epsolay - A Benzoyl Peroxide Cream for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
AND LACTATION — Topical benzoyl peroxide is poorly absorbed and rapidly metabolized; use by pregnant ...
Epsolay (Galderma), a 5% benzoyl peroxide cream, has been approved by the FDA for treatment of inflammatory lesions of rosacea in adults. It is the first product containing benzoyl peroxide to be approved in the US for treatment of rosacea. Benzoyl peroxide formulations approved for acne have been used off-label to treat rosacea for years, but itching and burning have limited their use.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):21-2   doi:10.58347/tml.2023.1669c |  Show IntroductionHide Introduction

Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
Metabolism Endogenous degradation Half-life 36.4 hours (in cycle 1 in breast cancer patients) Table 2 ...
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested by febrile neutropenia, in adults with nonmyeloid malignancies receiving myelosuppressive chemotherapy that can cause clinically significant febrile neutropenia.
Med Lett Drugs Ther. 2023 May 29;65(1677):83-4   doi:10.58347/tml.2023.1677b |  Show IntroductionHide Introduction

Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024  (Issue 1696)
capsules Tmax ~2 hours Metabolism CYP450 and non-CYP450 (sulfation and glucuronidation) Elimination ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with mCRC regardless of biomarker status. Fruquintinib is the first drug to become available in the US for treatment of mCRC that targets 3 VEGF receptor kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5   doi:10.58347/tml.2024.1696f |  Show IntroductionHide Introduction